We are unlocking the full potential of regenerative medicine through our innovative extracellular vesicles (EVs) technology.
Our EV products are inspired by the body’s own healing mechanisms, capturing the therapeutic power of stem cells, without the hurdles and limitations of traditional cell-based therapies.
With our EV therapeutics we aim to address critical unmet medical needs, by ensuring reproducibility, scalability and safety.
Products
Based on our stem cell technology platforms, Phoenestra provides access to a wide variety of promising cell-based product candidates for R&D, drug discovery and therapeutic applications. From the start we have the requirements of the final product in mind.
The selection of donors and donor materials is performed with all safety, ethical and legal requirements in place. For iPS cell-derived products, Phoenestra is currently establishing an end-to-end approach from urine sampling to release of GMP-grade products. For MSC-based products, we provide a one-stop-shop concept in collaboration with Evercyte (stable cell lines, potency assays) and TAmiRNA, the expert company in RNA profiling and biomarker development.
EVscale™ is our world-leading technology platform for manufacturing biologically active EV with consistent quality and in clinically relevant quantities from small manufacturing footprints. With this tech platform, we are the ideal partner for your EV/exosome product development project. Please refer also to the EVscale™ Catalogue in the Resources section.
Interested? Please contact us for more details!
MSC
Mesenchymal Stem (Stromal) Cells
• Immortalized MSCs from our partner company Evercyte:
• Extended lifespan
• Reproducible growth
• Eliminated donor variability
• GMP-ready Cell Lines
• Tiered cell banking
• Expansion in 2D and 3D (cultivation on microcarriers)
• Characterization:
• Cell growth and morphology
• Surface marker analysis
• Differentiation
EV
Extracellular vesicles (Exosomes)
• Production in stirred tank bioreactors
• Scalable and controlled
• Xeno-free and hPL-free
• Gentle downstream processing
• Extensive characterization:
• Particle concentration
• Particle size
• Marker phenotype
• Protein concentration
• CD73 activity
• biological activity assays
• miRNA analysis (TAmiRNA)
• In-vivo data available
iPSC
Induced Pluoriputent Stem Cells
• Generation from urine, other body fluids or tissues
• Expansion in 2D and 3D (shake flasks or stirred tank bioreactors)
• Xeno-free
• Cell banking and characterization:
• Cell growth and morphology
• Pluripotency marker analysis
• Karyotyping
• Differentiation
Technology Platform / Services
Phoenestra offers capabilities and resources also on a fee-for-service basis and dependent on your specific project needs. Please contact us for a discussion on options and opportunities for R&D work or a collaboration regarding GMP manufacturing services. Or simply send us your “Request for Proposal (RfP)”
R&D
- Cell line development (xeno-free iPS cell lines)
- Cell banking (iPSC, MSC)
- Process and product development
- Process and product characterization
- EVscaleTM - Extracellular Vesicles at scale from different GMP-ready MSC/TERT cell lines at quantities up to 1x1013 EV per batch (TFF retentate)
- EV from other cell types
GMP (please contact us for timelines)
- GMP Cell banking
- Pre-clinical and early clinical supplies
Partners / Network
Publications / Resources
Get in touch.
For enquiries regarding our technology platforms, products and services, please contact
phoenestra.com
For any general inquiries or in case you are interested to join our team, please contact